A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approval

Urol Oncol. 2015 Mar;33(3):115. doi: 10.1016/j.urolonc.2014.12.004. Epub 2015 Jan 22.

Authors

Gabriel P Haas¹, Howard I Scher²

Affiliations

¹ Astellas Global Medical Affairs, Northbrook, IL; Department of Urology, Loyola University School of Medicine, Maywood, IL. Electronic address: [email protected].
² Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY.

PMID: 25620153
DOI: 10.1016/j.urolonc.2014.12.004

No abstract available

Publication types

Editorial
Introductory Journal Article

MeSH terms

Biological Products / therapeutic use
Biomarkers, Tumor
Clinical Trials as Topic
Drug Approval*
Drug Design*
Drug Industry / trends
Humans
Medical Oncology / methods*
United States
United States Food and Drug Administration
Urologic Neoplasms / drug therapy
Urology / methods*

Substances

Biological Products
Biomarkers, Tumor